Skip to main content

and
  1. Article

    Open Access

    Proteomic profiling of gastric cancer with peritoneal metastasis identifies a protein signature associated with immune microenvironment and patient outcome

    Peritoneal metastasis (PM) frequently occurs in patients with gastric cancer (GC) and is a major cause of mortality. Risk stratification for PM can optimize decision making in GC treatment.

    Yanyan Chen, Guoxin Cai, Junjie Jiang, Chao He, Yiran Chen, Yongfeng Ding in Gastric Cancer (2023)

  2. No Access

    Article

    miR-183-5p promotes proliferation, invasion, and glycolysis of thyroid carcinoma cells by targeting FOXO1

    The aim of this study was to research the influences of miR-183-5p on the proliferation, invasion, and glycolysis of thyroid cancer (THCA) cells. Clinical specimens from 84 THCA patients were included. THCA ce...

    Chun Han, Kangnan Mo, Lin Jiang, Ke**g Wang in Molecular and Cellular Biochemistry (2022)

  3. Article

    Letter to the editor: new response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor

    Junjie Jiang, Lisong Teng in Gastric Cancer (2021)

  4. Article

    Comment on: “Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study. Gastric cancer, 2021 Aug 5” by Kim et al.

    Junjie Jiang, Lisong Teng in Gastric Cancer (2021)

  5. Article

    Open Access

    A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics

    Gastric cancer (GC) is one of the leading causes of cancer deaths with high heterogeneity. There is currently a paucity of clinically applicable molecular classification system to guide precise medicine.

    Haiyong Wang, Yongfeng Ding, Yanyan Chen, Junjie Jiang, Yiran Chen in Gastric Cancer (2021)

  6. Article

    Open Access

    Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study

    Combining chemotherapy with immunotherapy improves the therapeutic outcome for first-line (1L) patients with advance nonsmall-cell lung cancer (NSCLC). Two cohorts of a phase 1b study (NCT02937116) aimed to ev...

    Hai** Jiang, Yulong Zheng, Jiong Qian, Chenyu Mao in Cancer Immunology, Immunotherapy (2021)

  7. Article

    Open Access

    SOX4 promotes the growth and metastasis of breast cancer

    Increasing evidence has shown that the transcription factor SOX4 is closely associated with the development and progression of many malignant tumors. However, the effect of SOX4 on breast cancer is unclear. In...

    **g Zhang, Chunhua **ao, Zhenbo Feng, Yun Gong, Baohua Sun in Cancer Cell International (2020)

  8. Article

    Open Access

    Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

    Sintilimab blocks the interaction between programmed death-1 (PD-1) and its ligands. The safety and efficacy of sintilimab combined with oxaliplatin/capecitabine (CapeOx) as first-line treatment were evaluated...

    Hai** Jiang, Yulong Zheng, Jiong Qian, Chenyu Mao, **n Xu, Ning Li in BMC Cancer (2020)

  9. Article

    Open Access

    Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways

    Targeted therapies are emerging treatment options for gastric cancer (GC). Patient-derived tumor xenograft(PDX) models of GC closely retain the features of the original clinical cancer, offering a powerful too...

    Haiyong Wang, Jun Lu, Jian Tang, Shitu Chen, Kuifeng He, **aoxia Jiang in BMC Cancer (2017)

  10. No Access

    Article

    A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer

    Paclitaxel and S-1 are both effective antitumor chemotherapeutic agents for advanced gastric cancer. However, the continuous administration of S-1 for 3 weeks or more can result in unacceptable toxicities, pa...

    Hai** Jiang, Jiong Qian, Peng Zhao in Cancer Chemotherapy and Pharmacology (2015)

  11. No Access

    Article

    A more sensitive platform for the detection of low-abundance BRAFV600E mutations

    Identifying low-abundance mutations is important for the therapy and diagnose of cancer. Since the potential for tumor heterogeneity, the efficient detection of cancer-relevant mutations largely depends on the...

    Weiqin Jiang, Weibin Wang, FangFang Fu in Molecular and Cellular Biochemistry (2012)